Five-Year Outcomes of FOLFIRINOX vs Gemcitabine as Adjuvant Therapy for Pancreatic Cancer

Conroy, Thierry; Castan, Florence; Lopez, Anthony; Turpin, Anthony; Ben Abdelghani, Méher; C. Wei, Alice; Mitry, Emmanuel; Biagi, James; Evesque, Ludovic; Artru, Pascal; Lecomte, Thierry; Assénat, Eric; Bauguion, Lucile; Ychou, Marc; Bouché, Olivier; Monard, Laure; Lambert, Aurélien; Hammel, Pascal; Cancer Trials Group and the Unicancer-GI–PRODIGE Group, Canadian; François, Éric; Ramée, Jean‐François; Castanie, H.; Pracht, Marc; Ghiringhelli, François; Maillard, Emmanuel; Couffon, Caroline; Volet, Julien; Bourgeois, Vincent; Chauvenet, Marion; Blanc, Jean‐Frédéric; Péré-Vergé, Denis; de la Fouchardière, Christelle; Adenis, Antoine; El Hajbi, Farid; Bennouna, Jaafar; Texereau, Patrick; Faroux, Roger; Miglianico, Laurent; Platini, Christian; Legoux, Jean-Louis; Caroli‐Bosc, François‐Xavier; Bouhier‐Leporrier, Karine; Gagnaire, Alice; Granger, Victoire; Lebrun-Ly, Valérie; Guimbaud, Rosine; Touchefeu, Yann; Gasmi, Mohamed; FIORE, Frédéric; François Seitz, Jean; Etienne, Pierre-Luc; Poisson, Catherine; Rinaldi, Yves; Baba-Hamed, Nabil; Bachet, Jean‐Baptiste; Aparicio, Thomas; Choné, Laurence; Guillet, Marielle; Forestier, Julien; Terrebonne, Éric; Hebbar, Mohamed; Breysacher, Gilles; André, Thierry; Khemissa-Akouz, Faiza; Hautefeuille, Vincent; Guerin‐Meyer, Véronique; Hartwig, Johannes; Bécouarn, Y.; Malka, David; Louvet, Christophe; Raoul, Jean‐Luc; Cany, Laurent; Juzina, Beata; Jouffroy, C.; Gourgou, Sophie; Rassouli, Mohammad; Chalchal, Haji; J. Renouf, Daniel; Wong, Ralph; Lemay, Frédéric; Aubin, Francine; Couture, Félix; Mc Whirter, Elaine; Welch, Stephen; Kavan, Petr; Findlay, B.; Cripps, C.; Andrés-Cano, P.; Ahmed, Shahid; Harb, Mohammed; Pressnail, Bryn; Dowden, Scott; J. O’Callaghan, Chris

doi:10.1001/jamaoncol.2022.3829

Public

Five-Year Outcomes of FOLFIRINOX vs Gemcitabine as Adjuvant Therapy for Pancreatic Cancer

Published in JAMA Oncology • Sep 1, 2022

Authors:

Thierry Conroy

Florence Castan

Anthony Lopez

Abstract

Importance: Early results at 3 years from the PRODIGE 24/Canadian Cancer Trials Group PA6 randomized clinical trial showed survival benefits with adjuvant treatment with modified FOLFIRINOX vs gemcitabine in patients with resected pancreatic ductal adenocarcinoma; mature data are now available. Obje...

Subject

Medicine

Gemcitabine

FOLFIRINOX

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!